Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America

Knight Therapeutics Inc has acquired exclusive rights from Incyte Corporation INCY to distribute tafasitamab and pemigatinib (Pemazyre) in Latin America.
Related: Incyte's Pemazyre Wins Conditional Approval For Bile Duct Cancer In Canada.
Under the agreement terms, Incyte will be responsible for developing, manufacturing, and supplying tafasitamab and pemigatinib.
Knight will be responsible for seeking the necessary regulatory approvals distributing both medicines in Latin America.
Tafasitamab, in combination with lenalidomide, is approved in the U.S and Europe for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).
Pemigatinib is approved in the U.S., Europe, and Japan for locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
Read Next: Back To Back FDA Approval For Incyte - This Time For Jakafi In GVHD.
Price Action: INCY stock is down 0.10% at $69.52 during the market session on the last check Thursday.